Dataset Information

Origin of Spectral Blue Shift of Lu3+-Codoped YAG:Ce3+ Phosphor: First-Principles Study.

ABSTRACT: Lu3+, with the smallest ionic radii in lanthanide ions, is an important and beneficial cation for tuning spectrum shifting toward a longer wavelength by ion substitution in many phosphors for solid-state lighting. However, in the Lu3+-substituted garnet system, the phosphor always has smaller lattice parameters and exhibits a shorter emission wavelength than other garnet phosphors. The mechanism of such a spectral blue shift induced by the Lu3+-codoped garnet phosphor is still unclear. In this study, the local and electronic structures of Lu3+-codoped and Lu3+-undoped YAG:Ce3+ phosphor have been studied by first-principles calculation to reveal the origin of the spectral blue shift. Our results provide a full explanation of the experimental data and the methodology, which is useful to understand and design garnet phosphors with tunable emission characteristics.

SUBMITTER: Zhong J

PROVIDER: S-EPMC6644831 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Origin of Spectral Blue Shift of Lu3+-Codoped YAG:Ce3+ Phosphor: First-Principles Study.

Zhong Jiyou J Zhao Weiren W Zhuang Weidong W Xiao Wei W Zheng Yaling Y Du Fu F Wang Ligen L

ACS omega 20170919 9

Lu3+, with the smallest ionic radii in lanthanide ions, is an important and beneficial cation for tuning spectrum shifting toward a longer wavelength by ion substitution in many phosphors for solid-state lighting. However, in the Lu3+-substituted garnet system, the phosphor always has smaller lattice parameters and exhibits a shorter emission wavelength than other garnet phosphors. The mechanism of such a spectral blue shift induced by the Lu3+-codoped garnet pho ...[more]

PMID: 31457847

Similar Datasets

Project description:BackgroundRadiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [177Lu]Lu-rhPSMA-10.1 and -10.2 have been synthesized and initially characterized in preclinical experiments with the aim to provide an optimized binding profile to human serum albumin, a reduction of charge, and thus accelerated kidney excretion, and unaffected or even improved tumor uptake. As both isomers showed similar in vitro characteristics and tumor uptake at 24 h post injection in tumor bearing mice and in order to identify the isomer with the most favorable pharmacokinetics for radioligand therapy, we carried out in-depth biodistribution and dosimetry studies in tumor-bearing and healthy mice.ResultsrhPSMA-10.1 and -10.2 were radiolabeled with lutetium-177 according to the established procedures of other DOTA-based PSMA ligands and displayed a high and comparable stability in all buffers and human serum (> 97%, 24 h). Biodistribution studies revealed fast clearance from the blood pool (0.3-0.6%ID/g at 1 h) and other background tissues within 48 h. Distinctive differences were found in the kidneys, where [177Lu]Lu-rhPSMA-10.1 displayed lower initial uptake and faster excretion kinetics compared to [177Lu]Lu-rhPSMA-10.2 expressed by a 1.5-fold and ninefold lower uptake value at 1 h and 24 h in healthy animals, respectively. Tumor uptake was comparable and in the range of 8.6-11.6%ID/g for both isomers over 24 h and was maintained up to 168 h at a level of 2.2 ± 0.8 and 4.1 ± 1.4%ID/g for [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2, respectively.ConclusionOur preclinical data on biodistribution and dosimetry indicate a more favorable profile of [177Lu]Lu-rhPSMA-10.1 compared to [177Lu]Lu-rhPSMA-10.2 for PSMA-targeted radioligand therapy. [177Lu]Lu-rhPSMA-10.1 shows fast kidney clearance kinetics resulting in excellent tumor-to-organ ratios over a therapy relevant time course. Meanwhile, [177Lu]Lu-rhPSMA-10.1 is currently being investigated in clinical phase I/II studies in patients with mCRPC (NCT05413850), in patients with high-risk localized PC (NCT06066437, Nautilus Trial) and after external beam radiotherapy (NCT06105918).

Project description:BackgroundIndividualized dosimetry is recommended for [177Lu]Lu-PSMA radioligand therapy (RLT) which is resource-intensive and protocols are often not optimized. Therefore, a simulation study was performed focusing on the determination of efficient optimal sampling schedules (OSS) for renal and tumour dosimetry by investigating different numbers of time points (TPs).MethodsSampling schedules with 1-4 TPs were investigated. Time-activity curves of the kidneys and two tumour lesions were generated based on a physiologically based pharmacokinetic (PBPK) model and biokinetic data of 13 patients who have undergone [177Lu]Lu-PSMA I&T therapy. Systematic and stochastic noise of different ratios was considered when modelling time-activity data sets. Time-integrated activity coefficients (TIACs) were estimated by simulating the hybrid planar/SPECT method for schedules comprising at least two TPs. TIACs based on one single SPECT/CT measurement were estimated using an approximation for reducing the number of fitted parameters. For each sampling schedule, the root-mean-squared error (RMSE) of the deviations of the simulated TIACs from the ground truths for 1000 replications was used as a measure for accuracy and precision.ResultsAll determined OSS included a late measurement at 192 h p.i., which was necessary for accurate and precise tumour TIACs. OSS with three TPs were identified to be 3-4, 96-100 and 192 h with an additional SPECT/CT measurement at the penultimate TP. Kidney and tumour RMSE of 6.4 to 7.7% and 6.3 to 7.8% were obtained, respectively. Shortening the total time for dosimetry to e.g. 96 h resulted in kidney and tumour RMSE of 6.8 to 8.3% and 9.1 to 11%, respectively. OSS with four TPs showed similar results as with three TPs. Planar images at 4 and 68 h and a SPECT/CT shortly after the 68 h measurement led to kidney and tumour RMSE of 8.4 to 12% and 12 to 16%, respectively. One single SPECT/CT measurement at 52 h yielded good approximations for the kidney TIACs (RMSE of 7.0%), but led to biased tumour TIACs.ConclusionOSS allow improvements in accuracy and precision of renal and tumour dosimetry for [177Lu]Lu-PSMA therapy with potentially less effort. A late TP is important regarding accurate tumour TIACs.

Dataset Information

Origin of Spectral Blue Shift of Lu3+-Codoped YAG:Ce3+ Phosphor: First-Principles Study.

Publications

Origin of Spectral Blue Shift of Lu<sup>3+</sup>-Codoped YAG:Ce<sup>3+</sup> Phosphor: First-Principles Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets